CME: Improving the treatment and management of schizophrenia: an overview of current and novel approaches
Cost: FreeView Offer chevron_right
Schizophrenia, by nature, presents manifold challenges to the HCP directing neuropsychiatric care. Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease. Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, they have sometimes been associated with poor patient adherence, which is associated with suboptimal clinical outcomes. In contrast, improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs.
By the end of the session the participant will be able to:
- Describe the pathophysiology of schizophrenia and the role the neurotransmitters receptors play in it: D2, D3, 5-HT2A
- Describe the benefits and risks of pharmacotherapy for schizophrenia and take them into account when formulating a treatment plan for different patients
- Formulate a treatment plan for a variety of patients with schizophrenia, including those exhibiting only negative symptoms
- Recommend therapy changes in patients who are unable to tolerate a prescribed treatment
- Identify barriers to care in patients with schizophrenia and develop** strategies to abate them
Healthcare professionals who are: psychiatrists and primary care physicians; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in psychiatry; and those who otherwise commonly care for or clinically encounter patients who have schizophrenia.